The UK is currently facing a critical issue with a widespread shortage of aspirin, a medication crucial for preventing strokes and heart attacks in vulnerable patients. The government has responded by adding aspirin to its export ban list, aiming to protect the supply for UK patients. This move comes as manufacturing delays are cited as the primary cause of the shortage.
Both the National Pharmacy Association (NPA) and the Independent Pharmacies Association report significant challenges in sourcing the drug. The NPA confirmed that pharmacists are being forced to ration stock, prioritizing patients with severe heart conditions or those requiring emergency prescriptions. The low-dose 75mg aspirin is particularly vital due to its antiplatelet effect, which prevents blood clots and helps avert heart attacks and strokes.
Doctors often prescribe aspirin for individuals who have experienced heart attacks or strokes, transient ischemic attacks, angina, peripheral arterial disease (PAD), or those who have undergone surgery. The NPA's survey revealed that 86% of UK pharmacies reported being unable to supply aspirin in the previous week, with the 75mg dose being the most affected.
Some pharmacies have even stopped selling aspirin over the counter. The NPA noted that the price of aspirin has risen due to the shortages, with a packet of 75mg dispersible tablets increasing from 18p to £3.90 in the last two months. This price hike is further exacerbated by the NHS's reimbursement rate of £2.18 per packet, leading to significant losses for pharmacies.
Olivier Picard, the NPA's chair, expressed concern over the inability of pharmacies to order aspirin and the potential impact on patients. He highlighted the broken pharmacy contract, emphasizing the need for government reform. Dr. Leyla Hannbeck, the chief executive of the Independent Pharmacies Association, echoed these sentiments, warning that the low stock levels are due to manufacturing delays and the inability to order sufficient quantities.
The issue is further complicated by the fact that the NHS's low prices for medicines often make manufacturers prioritize supplying other countries, pushing the UK to the back of the queue. This results in limited stock and skyrocketing prices when available, making it unaffordable for pharmacies. The government is urged to review medicine reimbursement to pharmacies to prevent worsening shortages.
The NPA advocates for reform of the rules restricting pharmacies from supplying alternative drugs or preparations. James Davies, the Community Pharmacy England director of research and insights, emphasizes the ongoing concern of medicine shortages for both patients and community pharmacies. Fiona Loud, the policy director at Kidney Care UK, highlights the impact on individuals with chronic kidney disease who rely on low-dose aspirin for stroke and heart attack prevention.
